News | Nuclear Imaging | June 29, 2015

North America Accounts for Highest Share of Global Nuclear Medicine Diagnostic Market

Fusion imaging and wide availability of radiopharmaceuticals expected to push market up nearly $7 billion by 2019

nuclear medicine diagnostic market, North America, PET, SPECT, Mordor

June 29, 2015 - The Global Nuclear Medicine Diagnostics Market report from Mordor Intelligence revealed that North America accounts for the highest share of the global nuclear medicine diagnostic market, followed by Europe and Asia-Pacific. Asian countries are expected to show a growing trend in the diagnostic sector because of increasing diagnostic procedure demand and the rise of the medical device industry.

The market is segmented into two major segments: single photon emission computed tomography (SPECT), which includes technetium-99m (TC-99m), thallium-201 (TL-201), iodine (I-123) and others; and positron emission tomography (PET), including fluorine-18, rubidium-82 (RB-82) and others. By application the market is segmented into SPECT (cardiology, lymphoma, thyroid, neurology and others) and PET (oncology, cardiology, neurology and others). By geography the market is segmented into North America, Europe and Asia-Pacific etc.

The global nuclear medicine diagnostic (PET and SPECT) market is expected to grow from an estimated $ 8.77 billion in 2014 to $15.51 billion in 2019, at an estimated compound annual growth rate (CAGR) of 12.08 percent.

Major factors for the growth of the market are increasing use of SPECT and PET in medical diagnostics, increased awareness about radiopharmaceuticals and ready availability of radiopharmaceuticals. It has novel applications for diseases such as Alzheimer's and a continually expanding oncology segment. However, some of the major constraints for the market are shorter half- life of radioisotopes, high capital investment, regulatory guidelines and reimbursement issues.

Until now, SPECT imaging was the mainstream modality for nuclear medicine applications like nuclear cardiology procedures. However, the trend is soon going to flip upside down because of a global shortage of molybdenum-99 isotope, which in turn will lead to a shortage of technetium-99, the daughter product of molybdenum. Hence, PET imaging products, which includes hybrid PET-CT scanners, holds a potential increase in market size in coming years. The cost associated with PET-CT service contracts is usually 105 percent of the system purchase price annually and can be as high as $275,000 per year.

The emerging market trend is fusion of nuclear imaging with different diagnostic imaging products such as PET/CT, SPECT/CT, and MRI/PET (magnetic resonance imaging). This provides a full gamut of imaging scans through the same unit and at the same time. The PET market is expected to witness more growth compared to SPECT imaging, as it provides higher resolution images, and the lack of availability of technetium-99m is propelling the industry to look for alternative diagnostic procedures.

Analyzing the application segment of SPECT and PET, PET is majorly being used in oncology because of good quality of imaging. SPECT, however, is mostly being used in the cardiology segment, accounting for almost 90 percent of the market share in cardiology. North America has totaled 5,729 PET procedures, while the number of PET procedures in the Asia-Pacific region is 369,636, owing to the increased demand of nuclear medicine diagnostic procedures in developing nations.

Major players in the market include Cardiarc Ltd., Digirad Corp., Gamma Medica Inc., GE Healthcare and Hologic Inc. Mergers and acquisitions of small and medium-sized manufacturers is another strategy being adopted by multinational players to enter in overseas markets.

For more information:

Related Content

CZT SPECT camera detectors offered by GE.

A display of CZT SPECT gamma camera detectors at RSNA 2016. These detectors are more sensitive than those used in older cameras, allowing for faster scans or lower radiation dose. 

Feature | Nuclear Imaging | September 19, 2017 | Dave Fornell
Cardiac nuclear myocardial perfusion imaging (MPI) has been a mature area of imaging for years, but has recently star
Videos | Nuclear Imaging | August 24, 2017
Prem Soman, M.D., director of nuclear cardiology at the Heart and Vascular Institute, University of Pittsburgh, and p
Videos | Nuclear Imaging | August 24, 2017
Randy Thompson, M.D., attending cardiologist, St.
cardiac nuclear myocardial perfusion imaging (MIP) exam guidelines for women
News | Nuclear Imaging | June 15, 2017
June 15, 2017 — The American Society of Nuclear Cardiology (ASNC) has published an updated consensus statement on evi
Videos | Nuclear Imaging | April 28, 2017
David Wolinsky, M.D., director of nuclear cardiology at Cleveland Clinic Florida and past-president of the American S
IBA Molecular, acquisition, Mallinckrodt Nuclear Imaging, nuclear imaging
News | Nuclear Imaging | January 30, 2017
IBA Molecular has successfully completed its acquisition of Mallinckrodt Nuclear Imaging, announced in August 2016,...
Medrad Intego PET Infusion System, recall
News | Nuclear Imaging | January 12, 2017
January 12, 2017 — Bayer Healthcare has initiated a recall of all its Medrad Intego PET Infusion System Source Admini
Nuclear cardiology, dose reduction, myocardial perfusion imaging
News | Nuclear Imaging | January 05, 2017
January 5, 2017 — Working in concert, the American Society of Nuclear Cardiology (ASNC), the Intersocietal Accreditat
PET, F-18 florbetaben, cardiac amyloidosis, Princess Alexandria Hospital

In a pilot study, F-18-florbetaben PET imaging appeared promising for differentiating between cardiac amyloidosis and hypertensive heart disease. Image courtesy of W. Phillip Law/Princess Alexandra Hospital, Brisbane, Australia.

News | Nuclear Imaging | December 06, 2016
Researchers at Princess Alexandra Hospital, Brisbane, Australia, have demonstrated that cardiac amyloidosis (abnormal...
Overlay Init